Christopher DelOrefice, a director at ResMed Inc, has acquired 554 shares of the company’s common stock. This transaction occurred on November 19, 2026, and was reported in a recent filing.
ResMed Inc, a company focused on surgical and medical instruments and apparatus, is known for its innovative healthcare solutions. The company is listed under the ticker symbol RMD and is based in San Diego, California.
According to the filing, the shares were acquired as part of a restricted stock unit (RSU) award. The filing noted, "Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2027, or the annual meeting of stockholders in the year following the grant date." Following this transaction, DelOrefice now owns a total of 2,977 shares of ResMed common stock.
This acquisition may impact various stakeholders, including investors and employees who are closely monitoring the company's leadership decisions. The surgical and medical instruments industry may take this as a sign of confidence from its executives, potentially influencing market perceptions.
The filing does not say what happens next.
The transaction was reported under Form 4, which is used to disclose changes in the ownership of a company's securities by corporate insiders. This particular filing was made on November 20, 2026, reflecting the transaction date of November 19, 2026.
Christopher DelOrefice is identified as a director of ResMed Inc, emphasizing his role in the company's governance. The filing also indicates that he has direct ownership of the shares acquired, as denoted by the code 'D' for direct ownership in the filing.
ResMed Inc's business address is listed as 9001 Spectrum Center Blvd, San Diego, CA 92123, where the company operates its headquarters. The company is incorporated in Delaware and is classified under the Standard Industrial Classification (SIC) code for surgical and medical instruments and apparatus.
The filing does not include any information about the potential impact of this transaction on ResMed's stock performance or any future plans for additional stock acquisitions by DelOrefice.
Read Next
Summit Therapeutics Co-CEO Exercises 300,000 Stock Options
Summit Therapeutics Co-CEO Exercises Stock Options for 300,000 Shares
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares






